Patients with metastatic kidney cancer may also have an primary lung cancer that has gone gone undiagnosed.
Studies presented in the last year demonstrated a revolutionary role for immune checkpoint inhibitors in the treatment of urothelial carcinoma.
Patients with advanced renal cell carcinoma (RCC) who discontinued anti-PD-1/PD-L1 immunotherapy early may still achieve durable responses.
Patients with advanced kidney cancer received broad-spectrum antibiotics less than a month before initiating immune checkpoint inhibitor therapy.
Alternating treatment with pazopanib and everolimus failed to prolong progression-free survival compared with continuous pazopanib.
Phase 2 studies have demonstrated that girentuximab possesses activity with a manageable safety profile for patients with clear cell renal cell carcinoma; therefore, in a phase 3 trial, researchers evaluated its efficacy and safety as adjuvant monotherapy.
Smoking-attributable cancer mortality estimates have not been established by state; therefore, in this study, the proportion of cancer deaths among persons 35 years and older related to cigarette smoking in 2014 was calculated for each state and DC.
Clinical Use of Cabozantinib in the Treatment of Advanced Kidney Cancer: Efficacy, Safety, and Patient SelectionOctober 13, 2016
[OncoTargets and Therapy] This research We reviews the development of cabozantinib in advanced renal cell carcinoma and its role in the treatment landscape.
A new class of drugs, that interferes with processes that fuel cell growth, is more effective and better tolerated that the standard-of-care drug for clear cell renal cell carcinoma.
Presence of certain microRNAs (miRNAs) is predictive of response to TKIs and prognosis for patients with metastatic renal cell carcinoma (mRCC).
Adding a second autologous hematopoietic cell transplantation (HCT) to standard therapy improves outcomes for pediatric patients with high-risk neuroblastoma.
Surgery to remove a cancerous kidney can often lengthen the lives of patients receiving targeted therapy for metastatic kidney cancer, but only approximately 3 in 10 such patients undergo the procedure.
A potential cancer therapy with a unique strategy to block the mTOR molecule has been designed. This new mTOR-inhibiting compound reduced the size of tumors resistant to earlier-generation mTOR inhibitors.
Several genetic differences uncovered in an analysis of data from The Cancer Genome Atlas (TCGA) are biologically plausible contributing factors for the worse survival of African American patients with clear cell renal carcinoma, even in the era of targeted therapy.
Adjuvant treatment with sorafenib or sunitinib demonstrated no survival benefit in patients with resected local renal cell carcinoma at high risk for disease recurrence.
Tumor Heterogeneity as a Rationale for a Multi-epitope Approach in an Autologous Renal Cell Cancer Tumor VaccineMarch 04, 2016
In this study, researchers sought to characterize a panel of 36 tumor-associated antigens and cellular marker proteins from tumor material of 133 patients with renal cell carcinoma who underwent radical neprhectomy.
Findings of the randomized, phase 3 METEOR trial demonstrate progression-free survival in patients with advanced renal cell carcinoma is improved with cabozantinib compared with everolimus.
Improvements to progression-free survival (PFS) seen across patient subgroups treated with cabozantinib.
This newly approved drug operates by targeting the PD-1/PD-L1 cellular pathway.
For patients with diabetes, poor glycemic control is linked to higher risk of postoperative progression.
The FDA extended indications for nivolumab (Opdivo) to include treatment of advanced (metastatic) renal cell carcinoma (RCC).
Genetic mutations in the REST gene have been shown to cause Wilms tumor, a rare kidney cancer that occurs in children. The findings identified mutations in the REST gene in 16 children with Wilms tumor.
Type 1 and type 2 carcinomas are characterized by specific genetic alterations; type 2 consists of at least three subtypes.
A recent study has linked an increased risk of kidney cancer to certain meat-cooking mutagens.
Independent risk factors for toxicity-related treatment discontinuation (TrTD) in patients with metastatic renal cell carcinoma (mRCC).
Frequent adverse events experienced by patients receiving tyrosine kinase inhibitors are hand-foot syndrome and mucositis/stomatitis.
Risk of Cardiovascular Events Higher After Antiangiogenic Therapy for RCC in Persons Older Than 65 YearsOctober 07, 2015
Sunitinib and sorafenib may be associated with an increased risk of cardiovascular events in older patients with renal cell carcinoma (RCC).
A new drug is proven more effective than standard therapies for advanced kidney cancer in patients with demonstrated drug resistance.
In new clinical trial, Nivolumab raised median survival for patients with advanced renal-cell carcinoma.
Four drugs that were recently approved by the FDA for the treatment of kidney cancer are being doubted for their clinical application.
- Antiperspirants/Deodorants and Breast Cancer (Fact Sheet)
- Novel Blood Test Detects Cancer, Locates Tumor Without Invasive Procedures
- Cabozantinib Activates Innate Immune Response, Eliminating Prostate Cancer
- Shorter Treatment of Breast Cancer with Trastuzumab May Lead to Improved Results
- Colorectal Cancer Rates Increased Sharply Among Generation X and Millennials
- Early Palliative Care Reduced ICU Use in Patients With Advanced Cancer
- Ginger Extract Raises Antioxidant Levels in Patients Undergoing Chemotherapy
- Nurse Navigators Improve Physician Engagement in Pretreatment Discussions
- Screening Increases Early Palliative Care, Reduces Aggressive EOL Measures
- Antiperspirants/Deodorants and Breast Cancer (Fact Sheet)
- Genome Sequencing Explains Resistance to CTLA-4 and PD-1 Inhibitors in Metastatic Melanoma
- Lifestyle Choices Have Greater Influence on Colon and Rectal Cancer Risk
- Kidney Cancer Metastases in Lung May Hide Undiagnosed Primary Lung Cancer
- Nasal Biomarker in Smokers Could Predict Lung Cancer
- Arm Lymphoscintigraphy After Axillary Lymph Node Dissection or Sentinel Lymph Node Biopsy in Breast Cancer
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|